January 16, 2021

ilchiodofisso

justice always right

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BRY, NERV and OTGLY

The MarketWatch News Department was not involved in the creation of this content. January 06,...

The MarketWatch News Department was not involved in the creation of this content.

January 06, 2021 (ACCESSWIRE via COMTEX) —
NEW YORK, NY / ACCESSWIRE / January 6, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Berry Corporation (NASDAQ:BRY)

Lawsuit on behalf of investors who purchased: (a) Berry common stock pursuant and/or traceable to the Company’s initial public offering conducted on or about July 26, 2018; or (b) Berry securities between July 26, 2018 and November 3, 2020, both dates inclusive

Lead Plaintiff Deadline: January 21, 2021

According to the complaint, Berry Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Berry had materially overstated its operational efficiency and stability; (ii) Berry’s operational inefficiency and instability would foreseeably necessitate operational improvements that would disrupt the Company’s productivity and increase costs; (iii) the foregoing would foreseeably negatively impact the Company’s revenues; and (iv) as a result, the Offering Documents and the Company’s public statements were materially false and/or misleading and failed to state information required to be stated therein.

Learn about your recoverable losses in BRY: http://www.kleinstocklaw.com/pslra-1/berry-corporation-loss-submission-form?id=11984&from=1

Minerva Neurosciences, Inc. (NASDAQ:NERV)

Class Period: May 15, 2017 – November 30, 2020

Lead Plaintiff Deadline: February 8, 2021

The complaint alleges Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company’s plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in NERV: http://www.kleinstocklaw.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?id=11984&from=1

CD Projekt S.A. (OTC PINK:OTGLY)

Class Period: January 16, 2020 – December 17, 2020

Lead Plaintiff Deadline: February 22, 2021

Throughout the class period, CD Projekt S.A. allegedly made materially false and/or misleading statements and/or failed to disclose that: Throughout the class period, defendants were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Cyberpunk 2077 was virtually unplayable on the current-generation Xbox or Playstation systems due to an enormous number of bugs; (2) as a result, Sony would remove Cyberpunk 2077 from the Playstation store, and Sony, Microsoft and the Company would be forced to offer full refunds for the game; (3) consequently, the Company would suffer reputational and pecuniary harm; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in OTGLY: http://www.kleinstocklaw.com/pslra-1/cd-projekt-s-a-loss-submission-form?id=11984&from=1

Image: http://www.kleinstocklaw.com/wp-content/uploads/2021/01/Klein-newsfile-logo220x220.png

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

[email protected]

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com:

https://www.accesswire.com/623390/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-BRY-NERV-and-OTGLY

COMTEX_377324781/2457/2021-01-06T20:30:25

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2021 ACCESSWIRE

The MarketWatch News Department was not involved in the creation of this content.